A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT ID: NCT05776472
Last Updated: 2025-05-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2023-06-26
2029-08-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy
NCT05646524
Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
NCT05270837
Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)
NCT01212744
Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT05731050
A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks
NCT01560286
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study plans to include approximately 200 patients at 70 sites in Europe, Middle East, Canada and Australia. Additional countries may be added in the study if necessary. Patients meeting the eligibility criteria will be enrolled in the study and followed prospectively for approximately 36 months. Patient data will be collected from start of pegcetacoplan treatment to end of follow-up. Retrospective data on pegcetacoplan will be captured from the time of pegcetacoplan treatment initiation. Pegcetacoplan treatment data will be collected for a minimum of approximately 36 months and up to a maximum of approximately 72 months, including retrospective period depending on when the patient started pegcetacoplan treatment. After pegcetacoplan treatment discontinuation, patients will remain in the study for 8 weeks to capture any AEs. Patients will come to their routine visits and the available data from each visit will be collected.
The scope of the study is to collect both retrospective and prospective data. The main part of the study will be prospective, collecting data on effectiveness, safety, patient- and clinician-reported outcomes and health care resource use. The study will also collect retrospective data before pegcetacoplan treatment start, which will consist of information on PNH treatment, blood transfusions and healthcare resource use. Data will be collected for up to 12 months prior to pegcetacoplan treatment start. As patients may have been treated with pegcetacoplan for up to 12 months prior to enrollment, retrospective data may be collected for up to 24 months. This means that the total data collection period including both the retrospective and the prospective part is up to 48 (+/- 3) months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pegcetacoplan
Pegcetacoplan will be prescribed according to the label in patients with PNH.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient started routine treatment with pegcetacoplan for PNH up to 12 months before enrollment or prescribed pegcetacoplan at enrollment. Decision to initiate treatment shall be made by the treating physician and independently from the decision to include the patient in the study.
* Patient is willing and able to provide written informed consent to participate in the study in a manner approved by the Institutional Review Board/Independent Ethics Committee and local regulations.
Exclusion Criteria
* Initiated current treatment with pegcetacoplan in an interventional study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Iqvia Pty Ltd
INDUSTRY
Swedish Orphan Biovitrum
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Liverpool Hospital
Liverpool, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Sunshine Coast University Hospital
Birtinya, Queensland, Australia
AZ Sint-Jan
Bruges, , Belgium
CHU Brugmann-Site Horta
Brussels, , Belgium
Centre Hospitalier Universitaire de Liege
Liège, , Belgium
AZ Turnhout - Campus Sint-Elisabeth
Turnhout, , Belgium
University Health Network
Toronto, Ontario, Canada
Hopital Maisonneuve-Rosemont d/b/a CIUSSS de l'Est-de-l'Île-de-Montréal
Montreal, Quebec, Canada
Fakultni nemocnice Brno
Brno, , Czechia
Ustav hematologie a krevni transfuze
Prague, , Czechia
Helsingin yliopistollinen keskussairaala
Helsinki, , Finland
CHU Nice - Hôpital de l'Archet 1
Nice, Alpes Maritimes, France
CHU de Bordeaux - Hôpital Haut-Lévêque
Pessac, Gironde, France
Hopital Foch
Suresnes, Hauts De Seine, France
CHU de Grenoble - Hôpital Albert Michallon
Grenoble, Isere, France
CHU de Nantes - Hotel Dieu
Nantes, Loire Atlantique, France
CHU de Nancy - Hôpital de Brabois Adultes
Vandœuvre-lès-Nancy, Meurthe Et Moselle, France
Hopital Claude Huriez - CHRU Lille
Lille, Nord, France
Hôpital Saint-Louis
La Defense, Paris, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, Rhone, France
CHU Poitiers
Poitiers, , France
Alb-Fils-Kliniken GmbH
Goettigen, Baden-Wurttemberg, Germany
Studienzentrum Aschaffenburg
Aschaffenburg, Bavaria, Germany
Universitaetsklinikum Frankfurt Goethe-Universitaet
Frankfurt am Main, Hesse, Germany
Universitaetsklinikum Giessen und Marburg GmbH Standort Giessen
Giessen, Hesse, Germany
Dres Ballo und Dr. Böck
Offenbach, Hesse, Germany
Universitaetsklinikum Essen
Essen, North Rhine-Westphalia, Germany
Universitaetsklinikum Leipzig AoeR
Leipzig, Saxony, Germany
Praxis Fenchel Saalfeld
Saalfeld, Thuringia, Germany
MV Zentrum für Onkologie und Hämatologie
Cologne, , Germany
Evangelismos Hospital
Athens, , Greece
University General Hospital "Attikon"
Athens, , Greece
University General Hospital of Larissa
Larissa, , Greece
G Papanikolaou General Hospital
Thessaloniki, , Greece
General Hospital of Thessaloniki "IPPOKRATEIO"
Thessaloniki, , Greece
DPC - Orszagos Hematologiai es Infektologiai Intezet
Budapest, , Hungary
Semmelweis Egyetem
Budapest, , Hungary
Semmelweis University
Budapest, , Hungary
Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
Bari, , Italy
Ospedale San Bassiano
Bassano del Grappa, , Italy
Irccs Aou Di Bologna- Pol. Di S.Orsola
Bologna, , Italy
Ospedale Oncologico Armando Businco
Cagliari, , Italy
Azienda Ospedaliera Universitaria Careggi
Florence, , Italy
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
Milan, , Italy
Ospedale San Raffaele
Milan, , Italy
Ospedale Maggiore della Carità
Novara, , Italy
Grande Ospedale Metropolitano - Presidio Morelli
Reggio Calabria, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, , Italy
Università di Roma La Sapienza
Rome, , Italy
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
Torino, , Italy
Uniwersytecki Szpital Kliniczny w Bialymstoku
Bialystok, , Poland
Szpital Uniwersytecki nr 2 im. dr J. Biziela w Bydgoszczy
Bydgoszcz, , Poland
Uniwersyteckie Centrum Kliniczne
Gdansk, , Poland
SPZOZ Szpital Uniwersytecki w Krakowie
Krakow, , Poland
WWCOiT in Lodz, Oddział Hematologii i Transplantologii
Lodz, , Poland
Uniwersytecki Szpital Kliniczny nr 1 w Lublinie
Lublin, , Poland
Warszawski Uniwersytet Medyczny
Warsaw, , Poland
Prince Faisal Bin Bandar Cancer Center
Buraidah, , Saudi Arabia
King Faisal Specialist Hospital & Research Center
Jeddah, , Saudi Arabia
King Faisal Specialist Hospital and Research Center - Madinah
Riyadh, , Saudi Arabia
King Faisal Specialist Hospital and Research Center - Riyadh
Riyadh, , Saudi Arabia
ICO Badalona - Hospital Universitari Germans Trias i Pujol
Badalona, , Spain
Hospital de Cruces
Barakaldo, , Spain
Hospital Clinic de Barcelona
Barcelona, , Spain
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital de Basurto
Bilbao, , Spain
Hospital Universitario Donostia
Donostia / San Sebastian, , Spain
Hospital Universitario Virgen de la Nieves
El Palmar, , Spain
Hospital Universitario de Gran Canaria Dr. Negrin
Las Palmas de Gran Canaria, , Spain
Hospital Lucus Augusti
Lugo, , Spain
Hospital Regional Universitario de Malaga
Málaga, , Spain
Hospital Universitario Central de Asturias
Oviedo, , Spain
Complejo Hospitalario Universitario de Santiago
Santiago de Compostela, , Spain
King's College Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sobi.PEGCET-304
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.